Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. reports developments tied to its antimicrobial wound care business, including commercialization of the revyve product line in the United States and Canada. The company is developing and marketing wound care treatments that target biofilms and wound bacteria, with revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser holding U.S. FDA 510(k) clearance; the gel and gel spray are also approved by Health Canada.
Recurring news includes financial results, distribution and sales-agent agreements, regulatory and quality-system updates, and scientific publications or conference presentations involving chronic wound and burn care research. Company updates also discuss operating expenses, continuing operations, and the discontinued animal health contract manufacturing activities that have affected recent results.
Kane Biotech (OTC:KNBIF) has engaged DNA Advisors as its exclusive financial advisor to conduct a comprehensive review of strategic opportunities intended to enhance shareholder value and support long-term growth. According to Kane, the review will consider strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations and other corporate transactions.
The company highlights that its revyve-branded Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray have received FDA 510(k) clearance in the United States and Health Canada approval, with commercial activities in both countries commencing in 2026, supported by added senior business development personnel. Kane emphasizes that there is no assurance the review will result in any specific transaction and has not set a completion timetable, stating it will only announce outcomes once a course of action is approved or disclosure is required by securities laws.
Kane Biotech (OTC:KNBIF) reported voting results from its June 24, 2026 annual and special shareholder meeting. About 83,622,028 shares, or 46% of outstanding common shares, were represented. All resolutions passed, including election of six directors, auditor appointment, and two equity-based compensation plans.
Shareholders approved a PRSU plan reserving 18,185,656 shares (10%) and a rolling stock option plan allowing issuance up to 10% of outstanding shares at grant.
Kane Biotech (OTC:KNBIF) reported Q1 2026 revenue of $43,218, down from $412,513 a year earlier, reflecting its transition from legacy animal health to focused human wound care and early commercialization of revyve.
Gross loss was $3,899, operating expenses fell to $669,402, and net loss improved to $714,827. Cash was $395,058, with a subsequent $1.16 million private placement. Kane expanded North American distribution, gained U.S. FDA 510(k) clearance for its revyve Antimicrobial Skin and Wound Cleanser, advanced clinical validation, and extended ISO 13485:2016 certification.
Kane Biotech (OTC:KNBIF) participated in the WCET–NSWOCC 2026 Joint Congress in Vancouver as an exhibitor and presenter, focusing on its revyve Antimicrobial Wound Gel, which is FDA cleared and authorized for sale in Canada.
The company presented a clinical case study on a complex diabetic foot ulcer, showing how rebalancing the wound environment supported progression toward healing and potentially improved quality of life. Kane Biotech engaged with global wound care clinicians, emphasizing education on biofilm, chronic wound challenges, and integrating antimicrobial approaches like revyve into standard care as part of its commercialization and global education strategy.
Kane Biotech (OTC:KNBIF) reported FY2025 revenue of $427,869 versus $2,080,879 in 2024 and a FY2025 net loss from continuing operations of $2,721,239. Cash at December 31, 2025 was $901,698. The company completed restructuring, closed multiple private placements and converted an insider loan to a five-year convertible debenture.
Regulatory and commercial progress includes Health Canada approval for revyve Gel Spray, U.S. FDA 510(k) clearance for revyve cleanser, new U.S. distribution agreements, and initial product shipments under a Marathon Medical partnership.
Kane Biotech (OTC:KNBIF) presented case-study clinical data for revyve at the SAWC Spring conference (April 8-12, 2026).
Highlights include >20-year venous leg ulcers reduced 85% at 33 weeks, complete pain elimination by week 6, 90% wound volume reduction in seven months for a tunneling wound, and wound pH falling from 8.0 to 6.8 in four weeks.
Kane Biotech (OTC:KNBIF) announced publication in Frontiers in Antibiotics on March 17, 2026, reporting that revyve Antimicrobial Wound Gel showed strong activity against antibiotic-tolerant biofilms in in vitro and ex vivo models.
The study reports elimination of mature Staphylococcus aureus and Pseudomonas aeruginosa biofilms, with large log-scale reductions and bacterial counts often below detectable limits within 24–72 hours. Revyve is US FDA 510(k) cleared and Health Canada approved.
Kane Biotech (OTC: KNBIF) announced a U.S. commercialization expansion on March 10, 2026, signing a distribution agreement with Marathon Medical and multiple independent U.S. contract sales representative agreements. Marathon provides federally authorized procurement pathways into the VA, DOD, and IHS, and Kane is building a contract sales team through 2026.
Kane Biotech (KNBIF) announced publication of a peer-reviewed article in the International Wound Journal on revyve Antimicrobial Wound Gel. The study reports a thermo-reversible gel with 99.99%–99.9999% bacterial reductions within 30 minutes, sustained in vitro activity up to 7 days, and porcine biocompatibility results. revyve holds US FDA 510(k) clearance and Health Canada approval, and the paper is first-authored by Kane R&D lead Dr. Jeyachchandran Visvalingam with collaborators from University of Miami.
Kane Biotech (OTC:KNBIF) signed non-exclusive U.S. distribution and sales agreements for its revyve Antimicrobial Wound Gel product line with Patient Care Medical (Austin, TX) and Life Biologics (Lakewood, NJ) on Feb. 19, 2026.
The products are FDA 510(k) cleared and Health Canada approved. Life Biologics will distribute nationally in advanced wound care; Patient Care Medical will cover Louisiana, Mississippi and the Gulf Coast. Preparations for initial shipments are underway in the near term.